LeprosyPhase 2/3NCT00919815
Ciclosporin in the Management of New Type 1 Reactions in Leprosy
A Phase 2/3 study testing Ciclosporin and Prednisolone in people with Leprosy, run by London School of Hygiene and Tropical Medicine at 1 site in Ethiopia.
Trial summary
Study 1A: Ciclosporin in the management of new Type 1 Reactions in Leprosy Objective: A randomised double blind controlled trial comparing Ciclosporin and Prednisolone,to determine whether treatment with Ciclosporin gives the same outcome in the treatment of new Type 1 Reactions as Prednisolone. Read more about this study
- Who is it for?
- Ages 18 to 65 years
- Conditions the study is for
- Leprosy
- What is being tested?
- Ciclosporin and Prednisolone
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 73 participants
- Where
- 1 siteEthiopia
- Study dates
- Aug 2010to Jul 2013
- Phase
- Phase 2/3
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 to 65 years
- All sexes
- No healthy volunteers
- Adult, Older adult
Who may be able to join
- Individuals with clinical evidence of T1R with new nerve function impairment (NFI).
- Aged 18-65
- Weigh more than 30Kg
Who cannot join
- Unwillingness to give informed consent
- Patients with severe active infections such as tuberculosis
- Pregnant or breastfeeding women (see Appendix II)
- Those with renal failure, abnormal renal function, hypertensive
- Patients taking thalidomide currently or within the last 3 months
- Patients not willing to return for follow-up
- Women of reproductive age not willing to use contraception for the duration of the study ( see Appendix II)
- HIV positive patients
Trial locations and contacts
1 site in 1 country.
About this study
Official title: A Randomised Double Blind Controlled Trial Comparing Ciclosporin and Prednisolone in the Treatment of New Leprosy Type 1 Reactions
Study 1A: Ciclosporin in the management of new Type 1 Reactions in Leprosy
Objective: A randomised double blind controlled trial comparing Ciclosporin and Prednisolone,to determine whether treatment with Ciclosporin gives the same outcome in the treatment of new Type 1 Reactions as Prednisolone.
Read the detailed description
We tested our hypothesis that ciclosporin would be as effective as prednisolone in the treatment of patients with leprosy reactions and nerve function impairment and that patients treated with ciclosporin would have fewer side effects than patients treated with prednisolone. A randomised controlled trial comparing ciclosporin and prednisolone in the treatment of acute leprosy T1R was conducted.
- Conditions
- Leprosy
- Being tested
- Ciclosporin, Prednisolone
- Keywords
- Leprosy, Type 1 Reactions, Prednisolone, Ciclosporin
- Medical subject headings
- Leprosy
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
CiclosporinDrug
Also called Cyclosporine, Cyclosporine A
Ciclosporin 7.5mg/kg - reducing regimen over 24 weeks (additional prednisolone given for the first four weeks)
PrednisoloneDrug
Also called corticosteroids
prednisolone 40mg daily then reducing regimen over 24 weeks
| Study group | Role | What they receive |
|---|---|---|
| ciclosporin arm | Experimental | ciclosporin reducing regimen lasting 24 weeks (additional prednisolone given for the first four weeks) Receives: Drug: Ciclosporin |
| prednisolone | Active comparator | standard course of prednisolone given in a reducing regimen over 24 weeks Receives: Drug: Prednisolone |
What is being measured
The primary outcome is the main question the study is designed to answer.
improvement in nerve function and Clinical Severity Score
Measured: at week 4, 20, 28
Secondary outcomes (6)
Incidence of adverse events
Measured: up to 36 weeks
Number of T1R recurrence episodes per patient in each treatment arm
Measured: up to 36 weeks
Severity of T1R recurrence for patients in each treatment arm
Measured: up to 36 weeks
extra prednisolone needed to control reaction
Measured: up to 36 weeks
6. Difference in score in Quality of Life assessment between start and end of treatment for patients in each treatment arm
Measured: 36 weeks
Mean time to recurrence of T1R for patients in each treatment arm
Measured: up to 36 weeks
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted12 Jun 2009 (estimated)
- Study startAug 2010
- Primary completionDec 2012
- Study completionJul 2013
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for LeprosyStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase 2/3
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- Double blind
- Who is masked
- Participant, Investigator
- Enrolment
- 73 participants (actual)
Sponsor and investigators
- Lead sponsor
- London School of Hygiene and Tropical Medicine
- Sponsor type
- University, hospital or other
- Collaborators
- Homes and Hospitals of St Giles, Alert Hospital, Ethiopia, Armauer Hansen Research Institute, Ethiopia
- Responsible party
- Principal investigator, Saba Lambert, London School of Hygiene and Tropical Medicine
- Investigators
- Diana Lockwood, MBChB, Principal investigator, London School of Hygiene and Tropical Medicine
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT00919815
- Sponsor's protocol ID
- ITCRBY24-T1RA
- Status last verified
- Mar 2015
- First submitted
- 11 Jun 2009
- Last updated
- 24 Mar 2015
- Results posted
- No
- Data monitoring committee
- Yes
Study at a glance
From the registry record, last updated by the sponsor on 24 Mar 2015. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- A Randomised Double Blind Controlled Trial Comparing Ciclosporin and Prednisolone in the Treatment of New Leprosy Type 1 Reactions
- ClinicalTrials.gov ID
- NCT00919815
- Acronym / sponsor ID
- ITCRBY24-T1RA
- Conditions
- Leprosy
- Keywords
- Leprosy, Type 1 Reactions, Prednisolone, Ciclosporin
- Phase
- Phase 2/3
- Study type
- Interventional
- Recruitment status
- Completed
- Enrolment
- 73 participants (actual)
- Lead sponsor
- London School of Hygiene and Tropical MedicineUniversity, hospital or other
- Collaborators
- Homes and Hospitals of St Giles, Alert Hospital, Ethiopia, Armauer Hansen Research Institute, Ethiopia
- Study start
- Aug 2010
- Primary completion
- Dec 2012 (actual)
- Study completion
- Jul 2013 (actual)
- First posted
- 12 Jun 2009 (estimated)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
Study 1A: Ciclosporin in the management of new Type 1 Reactions in Leprosy
Objective: A randomised double blind controlled trial comparing Ciclosporin and Prednisolone,to determine whether treatment with Ciclosporin gives the same outcome in the treatment of new Type 1 Reactions as Prednisolone.
Detailed description
We tested our hypothesis that ciclosporin would be as effective as prednisolone in the treatment of patients with leprosy reactions and nerve function impairment and that patients treated with ciclosporin would have fewer side effects than patients treated with prednisolone. A randomised controlled trial comparing ciclosporin and prednisolone in the treatment of acute leprosy T1R was conducted.
Study design
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- Double blind (participant, investigator)
- Number of arms
- 2
| Arm | Type | Receives |
|---|---|---|
| ciclosporin arm | Experimental | Drug: Ciclosporinciclosporin reducing regimen lasting 24 weeks (additional prednisolone given for the first four weeks) |
| prednisolone | Active comparator | Drug: Prednisolonestandard course of prednisolone given in a reducing regimen over 24 weeks |
Who may qualify
- Ages
- 18 to 65 years
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
Key inclusion criteria (3 listed)
- Individuals with clinical evidence of T1R with new nerve function impairment (NFI).
- Aged 18-65
- Weigh more than 30Kg
Key exclusion criteria (8 listed)
- Unwillingness to give informed consent
- Patients with severe active infections such as tuberculosis
- Pregnant or breastfeeding women (see Appendix II)
- Those with renal failure, abnormal renal function, hypertensive
- Patients taking thalidomide currently or within the last 3 months
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| CiclosporinAlso: Cyclosporine, Cyclosporine ACiclosporin 7.5mg/kg - reducing regimen over 24 weeks (additional prednisolone given for the first four weeks) | Drug | ciclosporin arm |
| PrednisoloneAlso: corticosteroidsprednisolone 40mg daily then reducing regimen over 24 weeks | Drug | prednisolone |
Primary outcome
improvement in nerve function and Clinical Severity Score
Time frame: at week 4, 20, 28
6 secondary outcomes
Incidence of adverse events
Time frame: up to 36 weeks
Number of T1R recurrence episodes per patient in each treatment arm
Time frame: up to 36 weeks
Severity of T1R recurrence for patients in each treatment arm
Time frame: up to 36 weeks
extra prednisolone needed to control reaction
Time frame: up to 36 weeks
6. Difference in score in Quality of Life assessment between start and end of treatment for patients in each treatment arm
Time frame: 36 weeks
Mean time to recurrence of T1R for patients in each treatment arm
Time frame: up to 36 weeks
Results and safety
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 24 Mar 2015.
Related trials for Leprosy
Not yet recruitingPhase 2
Telacebec in Adults With Multibacillary Leprosy (TEBULA Leprosy Trial)
Leprosy, Multibacillary
RecruitingPhase 2
Efficacy and Safety Study of Dovramilast in People With Leprosy Type 2 Reaction
Erythema Nodosum Leprosum
RecruitingObservational study
Identification of Cutaneous and Blood Biomarkers Predictive of Response to Systemic Treatments During Chronic Inflammatory Skin Diseases
Atopic Dermatitis, Psoriasis
RecruitingPhase 3
Bedaquiline Enhanced Post ExpOsure Prophylaxis for Leprosy
Leprosy
Recruiting
Accuracy of the Polymerase Chain Reaction of Ulnar Perineural Subcutaneous Aspirate Guided by Ultrasound for the Diagnosis and Monitoring of Leprosy Cure
Leprosy, Leprosy Neuropathy
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
Diana Lockwood, MBChB principal investigator
London School of Hygiene and Tropical Medicine
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A Phase 2/3 study testing Ciclosporin and Prednisolone in people with Leprosy, run by London School of Hygiene and Tropical Medicine at 1 site in Ethiopia.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 3 inclusion and 8 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: finished, as of the sponsor's last update on 24 Mar 2015. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in Ethiopia. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
What does this combined phase mean?
Phase 2 studies give the treatment to a larger group to see whether it has the intended effect and to keep checking safety.
Phase 3 studies compare the treatment with the current standard treatment or a placebo in a large group, to confirm how well it works and watch for side effects.
Not every study follows the same path, and some studies (observational studies, device studies) have no phase.
Are results available for this study?
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
improvement in nerve function and Clinical Severity Score (time frame: at week 4, 20, 28). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 24 Mar 2015.